Month: November 2022

Cooperative binding and stepwise encapsulation of drug molecules by sulfonylcalixarene-based metal-organic supercontainers was written by Sheng, Tian-Pu;Fan, Xin-Xia;Zheng, Guo-Zong;Dai, Feng-Rong;Chen, Zhong-Ning. And the article was included in Molecules in 2020.Related Products of 117976-90-6 The following contents are mentioned in the article:

The cooperative binding behavior of a face-directed octahedral metal-organic supercontainer featuring one endo cavity and six exo cavities was thoroughly examined in chloroform solution through UV-visible (UV-Vis) titration technique using two representative drug mols. as the guests. The titration curves and their nonlinear fit to Hill equation strongly suggest the efficient encapsulation of the guest mols. by the synthetic host, which exhibit interesting cooperative and stepwise binding behavior. Based on the control experiments using tetranuclear complex as a reference, it is clear that two equivalent of the guest mols. are initially encapsulated inside the endo cavity, followed by the trapping of six addnl. equivalent of the drug mols. through six exo cavities (1 equivalent per exo cavity), and the remaining guests are entrapped by the external pockets. The results provide an in-depth understanding of the cooperative binding behavior of metal-organic supercontainers, which opens up new opportunities for designing synthetic receptors for truly biomimetic functional applications. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Related Products of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Related Products of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Synthesis of dioctyl succinate catalyzed by task-specific ionic liquids under microwave irradiation and electrical heating was written by Long, Yu-lin;Chen, Bing;Yang, Jun;Yin, Wan-xiang. And the article was included in Huaxue Yanjiu Yu Yingyong in 2012.Computed Properties of C10H20N2O4S The following contents are mentioned in the article:

A series of task-specific ionic liquids(TSILs) that bear an alkane sulfonic acid group were synthesized. Esterification of succinic acid with octanol was investigated using these TSILs as catalysts in both microwave irradiation and traditional heating ways. Effect of the anion and cation of the TSILs on catalytic performance was also investigated. Compared with elec. heating way, TSILs exhibited an enhanced reaction efficiency and short reaction time under microwave irradiation Effect of catalyst amount, reaction time and the acid-to-alc. ratio on conversion of succinic acid was systematically investigated. The results showed that the conversion of succinic acid reached 95.74% by using[PSPy]HSO₄ as the catalyst under succinic acid/octanol molar ratio of 1:4, succinic acid mass fraction of 3wt% in TSILs, reaction temperature of 150°C, reaction time of 15 min and power of 400W. In addition, the [PSPy]HSO₄ exhibited excellent stability and catalytic activity. It could be reused six times without considerable loss of activity and still had a conversion of 93.58%. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Computed Properties of C10H20N2O4S).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Computed Properties of C10H20N2O4S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma was written by Lee, Hans C.;Feng, Lei;Oriabure, Onyeka;Graham, Vivian;Chen, Wendy;Badillo, Maria;Lu, Rebecca;Lee, Hun J.;Jain, Preetesh;Manasanch, Elisabet E.;Orlowski, Robert Z.;Wang, Michael L.. And the article was included in American Journal of Hematology in 2021.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:

The incorporation of novel agents including immunomodulatory drugs(IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs) to myeloma treatment regimens have led to substantial gains in overall survival in patients with multiple myeloma over the last 10-15 years. However, alkylating agents remain an important option in the myeloma therapeutic armamentarium, and their use in combination with novel agents have shown to be an effective treatment strategy for both newly diagnosed and relapsed and/or refractory myeloma patients. The primary endpoint of the study was to determine the MTD of carfilzomib, bendamustine and dexamethasone with dose-limiting toxicities (DLTs) assessed during the cycle one (28-day) DLT-evaluable period. In summary, we establish the MTD of the combination of carfilzomib, bendamustine, and dexamethasone in RRMM and demonstrate its encouraging preliminary efficacy in this phase one study. These data suggest that carfilzomib in combination with the alkylating agent bendamustine may be a useful and relevant treatment option in this patient population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Recommanded Product: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Kinetic study on esterification of biodiesel component prepared in acidic ionic liquids was written by Bo, Yang;Lu, Qinfang;Li, Guochao. And the article was included in Gongye Cuihua in 2010.Product Details of 478935-29-4 The following contents are mentioned in the article:

Four kinds of Brφnsted acidic ionic liquids with nitrogen chem. groups and different anions were synthesized. The kinetics of esterification of Me oleate was studied using Brφnsted acidic ionic liquids as the catalysts. Through experiments of kinetics and by Matlab programs and regression of the exptl. data, the reaction dynamics parameters were determined and the reaction dynamic model was set up. The catalytic activities of ionic liquids were investigated. The results that showed under the coaction of anions and cations, the kinetic equation of esterification was as follows: r=k(c_A0-x)^1.72(c_B0-x)^2.01-k_-1x^1.85, and the sequence of reaction rate constants k of nine kinds of ionic liquids in catalyst system was as follows: [MPy]HSO₄ > [Py]HSO₄ > [Et₃NH]HSO₄ > [MPy]H₂PO₄ > [Py]H₂PO₄ > [Et₃NH]H₂PO₄ > [HMIm]HSO₄ > [HMIm]H₂PO₄ > [MPy]NO₃. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Product Details of 478935-29-4).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Product Details of 478935-29-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Hydrophobic and hydrophilic interactions of ionic liquids and polymers in solid polymer gel electrolytes was written by Sutto, Thomas E.. And the article was included in Journal of the Electrochemical Society in 2007.Application of 157310-73-1 The following contents are mentioned in the article:

Poly(ethylene oxide), PEO, or poly(vinylidenefluoride-co-hexafluoropropene) (PVDF-HFP), and the ionic liquids 1-n-propyl-2,3-dimethylimidazolium tetrafluoroborate (MMPIBF₄) and 1-n-propyl-2,3-dimethylimidazolium hexafluorophosphate (MMPIPF₆) with and without 0.5 M Li salt were used to prepare solid polymer gel electrolytes. Experimentation indicated that for the PEO films, the 20 and 30 weight% polymer gels exhibited the highest ionic conductivity, although the 20 weight% film is fragile and exhibits poor mech. properties. Therefore, the composition of all gels studied is 30 weight% polymer and 70 weight% ionic liquid For all systems, addition of the lithium salts results in approx. a 33% drop in ionic conductivity For the formation of polymer gel electrolytes, selection of a nonpolar polymer paired with a hydrophobic electrolyte results in greater ionic conductivity and reversibility in the intercalation of Li ion into graphite. These results are interpreted in terms of the type of solid solution formed between the hydrophobic and hydrophilic polymers and the ionic liquids This study involved multiple reactions and reactants, such as 1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V) (cas: 157310-73-1Application of 157310-73-1).

1,2-Dimethyl-3-propyl-1H-imidazol-3-ium hexafluorophosphate(V) (cas: 157310-73-1) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Application of 157310-73-1

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study was written by Allsup, David;Howard, Dena;Emmerson, Jake;Hockaday, Anna;Rawstron, Andy;Oughton, Jamie B.;Bloor, Adrian;Phillips, David;Nathwani, Amit;Paneesha, Shankara;Turner, Deborah;Munir, Talha;Hillmen, Peter. And the article was included in British Journal of Haematology in 2021.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

This study designed a COSMIC phase II randomized controlled trial (RCT) in relapsed chronic lymphocytic leukemia (CLL) to test whether high dose ofatumumab based chemoimmunotherapy (CIT) was sufficiently efficacious to be investigated in larger trials. Ofatumumab was given in combination with investigators choice of chemotherapy comprising six cycles of either fludarabine and cyclophosphamide (FC) or bendamustine (B). The treatment schedule for sOf-FC/B was FC or B in combination with ofatumumab 300 mg day 1 cycle 1, ofatumumab 1000 mg day 8 Cycle 1, ofatumumab 1000 mg day 1 cycles 2-6 and treatment schedule for megaOf-FC/B was FC or B in combination with ofatumumab 300 mg day 1 cycle 1, ofatumumab 2000 mg, days 8, 15, 22 cycle 1, ofatumumab 2000 mg days 1, 8, 15, 22 cycle 2, ofatumumab 2000 mg day 1 cycles 3-6. Observed toxicities were compatible with those known for FC, B and ofatumumab with no excess infusional reactions in megaOf treated participants. Neither sOf or megaOf in combination with FC or B, reached pre-specified endpoints in terms of rates of CR/CRi to warrant further investigation. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bendamustine: a review of pharmacology, clinical use and immunological effects (review) was written by Lalic, Hrvoje;Aurer, Igor;Batinic, Drago;Visnjic, Dora;Smoljo, Tomislav;Babic, Antonija. And the article was included in Oncology Reports in 2022.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

A review. Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogs, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Considering its beneficial properties in the therapy of relapsed or refractory hematol. malignancies, synergistic effects with other antineoplastic agents and increasing recent reports on its immunomodulatory effects, bendamustine has once again gained its justified attention. The uniqueness of bendamustine-mediated effects should be observed keeping in mind its distinctive structure with structural similarities to both alkylating agents and purine analogs. In the present review, the current knowledge on the use of bendamustine in oncol., its pharmacokinetics, mechanism of action and toxicity was summarized. In addition, its immune-modulating effects that have not been fully elucidated so far are emphasized, hoping to encourage further investigations of this unique drug. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma was written by Nakamura, Nobuhiko;Kasahara, Senji;Kitagawa, Junichi;Nakamura, Hiroshi;Sawada, Michio;Fukuno, Kenji;Shibata, Yuhei;Kaneda, Yuto;Hara, Takeshi;Kanemura, Nobuhiro;Tsurumi, Hisashi;Shimizu, Masahito. And the article was included in Experimental Hematology & Oncology in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:

This phase II clin. trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Thirteen patients were enrolled and received a median of 4 cycles (range 2-6) of BRAC. The complete response rate was 61.5%, and the overall response rate was 84.6%; the 2-yr overall survival was 76.9%, and the 2-yr progression-free survival was 69.2%. Although all patients received G-CSF prophylaxis, grade 3 or higher neutropenia was observed in all cycles, and the incidence of febrile neutropenia was 20%. Grade 4 thrombocytopenia was observed in 92.5% of all cycles, and platelet transfusion was performed in 94%. Although hematol. toxicity was relatively high, BRAC therapy was effective for relapsed and refractory FL or MCL. Further studies are needed to determine the optimal dose of BRAC therapy. Trial registration The UMIN Clin. Trials Registry, UMIN000009797. Registered 17 Jan. 2013, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000011103. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

An application of continuous flow microreactor in the synthesis and extraction of rabeprazole was written by Duan, Zhenya;Wang, Yan;Zhang, Ling;Cao, Xing;Fu, Lihua;Li, Zhenjiang;Zhang, Junmei. And the article was included in International Journal of Chemical Reactor Engineering in 2021.Category: imidazoles-derivatives The following contents are mentioned in the article:

The oxidation of rabeprazole sulfide is a key step in the synthesis of rabeprazole, a drug for the treatment of stomach acid-related disorders. The current rabeprazole production process adopts one pot batch process, which has low reaction efficiency and poor stability. A continuous process can greatly improve the production efficiency and solve the above problems. Therefore, the reaction parameters of rabeprazole in microreactor were explored through laboratory experiments to explore the possibility of continuous production of rabeprazole. Rabeprazole sodium was synthesized by using rabeprazole thioether as a raw material and sodium hypochlorite solution as the oxidant. Oxidation, quenching, acid-base regulation and extraction were completed continuously in the microreactor. Rabeprazole solution with a purity of 98.78% (±0.13%) can be obtained continuously in 56 s, whereas intermittent production lasted for at least 2 h. Thus, the microreactor can effectively improve the oxidation synthesis efficiency of rabeprazole, and provide reference for the realization of other reactions in the microreactor. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Category: imidazoles-derivatives).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia was written by Germain, Claire;Garibal, Julie;Doppler, Valerie;Baran-Marszak, Fanny;Cymbalista, Florence;Caumartin, Julien;Langlade-Demoyen, Pierre;Wehbe, Maria;Huet, Thierry. And the article was included in Clinical Immunology Communications in 2021.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:

Human telomerase reverse transcriptase (hTERT) is broadly expressed in many cancers. High hTERT expression have been described in chronic lymphocytic leukemia (CLL). Here we investigated the relationship between anti-hTERT immunity and disease progression in 49 CLL patients. Anti-hTERT T cell responses were evaluated by IFNγ-ELISpot. Complementary flow cytometry analyses were performed, and data were analyzed in regards of the treatment received by CLL patients afterward and disease progression. Anti-hTERT responses were more frequently observed in non-progressive watch and wait patients, and in progressive patients scheduled to receive ibrutinib, as compared to patients scheduled to receive other types of treatment. In vitro, addition of the anti-PD-1 antibody nivolumab increased anti-hTERT responses. Importantly, Kaplan Meier analyses showed significantly longer progression-free survival in patients with anti-hTERT immune responses at diagnosis as compared to non-responder patients. Our results show that anti-hTERT T cell responses represent a new potential biomarker predictive of CLL clin. outcome. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Synthetic Route of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem